Key result
Oral administration of the ASK1 inhibitor GS-444217 dose-dependently reduced pulmonary arterial pressure and right ventricular hypertrophy in preclinical rodent models of pulmonary arterial hypertension.
Why the study?
Does GS-444217 reduce pathological remodeling and halt progression of pulmonary hypertension in preclinical models?
Does GS-444217 reduce pathological remodeling and halt progression of pulmonary hypertension in preclinical models?
ASK1 inhibition with GS-444217 halts disease progression and reduces pathological remodeling of the pulmonary vasculature and right ventricle in preclinical models of pulmonary arterial hypertension.
Supports clinical development of ASK1 inhibitors for pulmonary arterial hypertension; leaves open translation from rodent models.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Budas et al. (2017) studied Pulmonary arterial hypertension. GS-444217 (ASK1 inhibitor) was evaluated on Pulmonary arterial pressure and right ventricular hypertrophy. Oral administration of the ASK1 inhibitor GS-444217 dose-dependently reduced pulmonary arterial pressure and right ventricular hypertrophy in preclinical rodent models of pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: